Catherine J. Friedman
Lead Independent DirectorMs. Catherine J. Friedman, also known as Cathy, serves as Director at Pelage Pharmaceuticals, Inc. and serves as its Chairman from October 2025. She is Independent Director of Altaba Inc. from March 2016. She is Executive Venture Partner of GV Management Company, LLC. She joined the GV Management Company, LLC in December 2021. She focused on Startups, Healthcare. She was Chair of the Board of GRAIL, LLC from December 10, 2018. She was Director of GRAIL, LLC from December 14, 2017 to December 10, 2018. She is Lead Independent Director of Lyell Immunopharma, Inc. from December 2021. She was Interim Chair & Lead Independent Director of Lyell Immunopharma, Inc. from September 29, 2021 to December 2021. She was Independent Director of Lyell Immunopharma, Inc. from August 2018 to September 29, 2021. She was Independent Director of Revolution Healthcare Acquisition Corp. She is Co-Owner of Lyell Investors, LLC. She was Director of Innoviva, Inc. until April 24, 2018. She was employed at Innoviva, Inc. from June 02, 2014 to April 24, 2018. She was Director of ReShape Lifesciences Inc. She was employed at ReShape Lifesciences Inc. from May 2007 to May 04, 2016. She was Independent Director of Radius Health, Inc. from August 19, 2015 to August 10, 2022. She was employed at Radius Health, Inc. from August 19, 2015 to August 10, 2022. She was Director of Xenoport, Inc. She was employed at Xenoport, Inc. from September 06, 2007 to July 05, 2016. She was Independent Director of Vividion Therapeutics, Inc. from March 2021. She was Director of Seer, Inc. from 2023 to December 21, 2023. She was Independent Director of Seer, Inc. from September 2020 to 2023. She was employed at Seer, Inc. from September 2020 to December 21, 2023. Ms. Friedman is a business executive with nearly 40 years of experience across finance, technology and healthcare. Ms. Friedman is currently an Executive Venture Partner at GV (Google Ventures), where she is a senior member of the investing team and advises the life sciences portfolio. Ms. Friedman has spent 17 years on the boards of leading public and private life sciences and technology companies. Earlier in her career, Ms. Friedman held numerous positions over a 23-year investment banking career with Morgan Stanley, including Managing Director from 1997 to 2006 and Head of West Coast Healthcare and Co-Head of the Biotechnology Practice from 1993 to 2006. Cathy holds a B.A. in Economics from Harvard University and an MBA from The University of Virginia’s Darden School of Business, where she serves as a Foundation Trustee.
Positions
- Company NameLyell Immunopharma, Inc.Stock CodeLYELPositionLead Independent DirectorColleagues
- RDRichard D. KlausnerFounder & Executive Chairman
- LSLynn SeelyPrincipal Executive Officer, President, CEO & Director
- SJStephen J. HillChief Operating Officer
- GKGary K. LeeChief Scientific Officer
- SRStanley R. RiddellFounder & Scientific Advisor
- WJWilliam JL RieflinIndependent Director
- OWOtis Webb BrawleyIndependent Director
